Stock-Based Compensation for Vertex Pharmaceuticals (VRTX)
Stock-Based Compensation for Vertex Pharmaceuticals (VRTX): headline value $685.90M · YoY -100.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingStock-Based CompensationSwitch metric
Latest period
$685.90M
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2024)
$698.50M
Latest annual
$0
Stock-Based Compensation history chart for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
Stock-Based Compensation history table for Vertex Pharmaceuticals (VRTX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $0 | -100.0% | ||
| 2024 | $698.50M | +20.2% | ||
| 2023 | $581.20M | +18.3% | ||
| 2022 | $491.30M | +11.3% | ||
| 2021 | $441.40M | +2.8% | ||
| 2020 | $429.50M | +19.1% | ||
| 2019 | $360.49M | +10.9% | ||
| 2018 | $325.05M | +11.8% | ||
| 2017 | $290.74M | +22.3% | ||
| 2016 | $237.71M | +2.9% | ||
| 2015 | $231.03M | +30.1% | ||
| 2014 | $177.54M | +39.5% | ||
| 2013 | $127.30M | +11.4% | ||
| 2012 | $114.28M | -9.8% | ||
| 2011 | $126.75M | +29.8% | ||
| 2010 | $97.68M | +12.6% | ||
| 2009 | $86.72M | +37.6% | ||
| 2008 | $63.01M | +6.1% | ||
| 2007 | $59.41M | +51.8% | ||
| 2006 | $39.14M | +419.7% | ||
| 2005 | $7.53M | +80.8% | ||
| 2004 | $4.17M | +32.4% | ||
| 2003 | $3.15M | +109.6% | ||
| 2002 | $1.50M | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — |
Stock-Based Compensation values are taken from Vertex Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Vertex Pharmaceuticals (VRTX) most recent annual stock-based compensation stands at $0 (2025) – plunged 100.0% year-over-year.
Vertex Pharmaceuticals stock-based compensation has contracted on net over the period, with a -100.0% compound annual growth rate over 2020–2025 (5 years).
Across the available history, stock-based compensation reached its high of $698.50M in 2024 and its low of $0 in 1991.
Vertex Pharmaceuticals (VRTX) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $313.00M.
Vertex Pharmaceuticals Stock-Based Compensation by Year
Vertex Pharmaceuticals Stock-Based Compensation 2025: $0
Vertex Pharmaceuticals stock-based compensation in 2025 was $0, plunged 100.0% below 2024.
Vertex Pharmaceuticals Stock-Based Compensation 2024: $698.50M
Vertex Pharmaceuticals stock-based compensation in 2024 was $698.50M, grew 20.2% from 2023. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Stock-Based Compensation 2023: $581.20M
Vertex Pharmaceuticals stock-based compensation in 2023 was $581.20M, grew 18.3% from 2022.
Vertex Pharmaceuticals Stock-Based Compensation 2022: $491.30M
Vertex Pharmaceuticals stock-based compensation in 2022 was $491.30M, grew 11.3% from 2021.
Vertex Pharmaceuticals Stock-Based Compensation 2021: $441.40M
Vertex Pharmaceuticals stock-based compensation in 2021 was $441.40M.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Stock-Based Compensation
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's stock-based compensation?
Latest reported stock-based compensation for Vertex Pharmaceuticals (VRTX) is $685.90M (period ending December 31, 2025).
How has Vertex Pharmaceuticals stock-based compensation changed year-over-year?
Vertex Pharmaceuticals (VRTX) stock-based compensation changed -100.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals stock-based compensation?
Vertex Pharmaceuticals (VRTX) stock-based compensation compound annual growth rate is -100.0% over the most recent 5 years available.
When did Vertex Pharmaceuticals stock-based compensation hit its highest annual value?
Vertex Pharmaceuticals stock-based compensation reached its highest annual value of $698.50M in 2024.
What was Vertex Pharmaceuticals stock-based compensation in 2024?
Vertex Pharmaceuticals (VRTX) stock-based compensation in 2024 was $698.50M.
What was Vertex Pharmaceuticals stock-based compensation in 2025?
Vertex Pharmaceuticals (VRTX) stock-based compensation in 2025 was $0.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.